Highlighting the Treatment Regimens used in COVID-19 epidemic in Iraq with Special Regards to Vitamin D

Authors

  • Zinah Mudhafar AL-Nema College of Pharmacy
  • Ruaa Natiq Yahya
  • Noor Mubdir Khalf

DOI:

https://doi.org/10.31351/vol31iss2pp223-232

Abstract

Coronavirus disease 2019 (COVID-19) is a flu-like infection caused by a novel virus known as Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). After the widespread around the world, it was announced by the World Health Organization (WHO) as a global pandemic. The symptoms of COVID-19 may arise within 2 weeks and the severity ranged from mild with signs of respiratory infection to severe cases of organ failure and even death. Management of COVID-19 patients includes supportive treatment and pharmacological medications expected to be effective with no definitive cure of the disease. The aims of this study are highlighting the management protocol and supportive therapy especially vitamin D and manifesting the clinical symptoms by patients in Iraq. An observational study was conducted on 200 patients and descriptive parameters for data were calculated to analyze the results. The mean age was 42.56±17.49 years and the majority of patients were presented with mild to moderate symptoms (78%). There were many different pharmacological treatment regimens and random doses and duration of vitamin D were taken by the patients. In conclusion, a non-specific treatment protocol was used for the patients without compliance to the national guidelines for management and treatment of COVID-19 patients in Iraq with the administration of a wide range of pharmaceutical agents that required monitoring for their safety and efficacy. Vitamin D is administered in different doses and duration without depending on the basal serum concentration.

References

Hannah Ritchie, Edouard Mathieu, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina, et al. Max (2020–2021). "Coronavirus Pandemic (COVID-19)". Our World in Data. Retrieved 29 October 2021.

Özdemir Ö. Coronavirus Disease 2019 (COVID-19): Diagnosis and Management (narrative review). Erciyes Med J. 2020;42(3):242–7.

Yousefifard M, Zali A, Mohamed Ali K, Madani Neishaboori A, Zarghi A, Hosseini M, et al. Antiviral Therapy in Man-agement of COVID-19: a Systematic Review on Current Evidence. Arch Acad Emerg Med. 2020;8(1):45.

Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–6.

Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1–13.

Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501–8.

Liang C, Tian L, Liu Y, Hui N, Qiao G, Li H, et al. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. Eur J Med Chem. 2020;201:112527.

Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient. Pharmacotherapy. 2020;40(6):592–8.

Frediansyah A, Tiwari R, Sharun K, Dhama K, Harapan H. Antivirals for COVID-19: A critical review. Clin Epidemiol Glob Heal. 2021;9(2020):90–8.

Sahu M, Kumar A, Shankar SH, Vishwakarma VK. Insights into the Mechanisms of Action of Chloroquine and Hydroxychloroquine and its Use in COVID-19 for Chemoprophylaxis. Journal of Primary Care Specialist. 2021; 2(2): 27-32.

Kashour Z, Riaz M, Garbati MA, AlDosary O, Tlayjeh H, Gerberi D, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis. J Antimicrob Chemother. 2021;76(4):30–42.

Tonkin-Crine S, Abel L, Van Hecke O, Wang K, Butler C. Tackling antimicrobial resistance in the community. Challenges to Tackling Antimicrob Resist. 2020;45–70.

Gautret P, Lagier J, Parola P, Hoang VT. Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1).

Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80(13):1267–92.

Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021;27(1):61–6.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–5.

Downloads

Published

2022-12-24